Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR
BJD, 2023.
Alabas OA, Mason KJ, Yiu ZZN, Hampton PJ, Reynolds NJ, Owen CM, Bewley A, Laws PM, Warren RB, Lunt M, Smith CH, Griffiths CEM; BADBIR Study Group.
Read publication: BJD
Related
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacoki...
Risk of Major Cardiovascular Events in Patients With Psoriasis Receiving Biologic Therapies: A Prosp...
The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celeb...
0 Comments